Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cholesterol drug
Biotech
YolTech sells China rights to gene editing therapy for $29M
In April, YolTech dosed the first patient in a phase 1 study of YOLT-101 for a genetic disorder characterized by high cholesterol levels.
James Waldron
Aug 27, 2024 10:24am
Chasing Merck, AstraZeneca's PCSK9 inhibitor lowers cholesterol
May 29, 2024 11:00am
Verve shows base editing works in humans—and sees stock sink
Nov 13, 2023 8:43am
LIB's cholesterol-busting drug hits goal in 2nd phase 3 trial
Aug 29, 2023 6:30am
Merck bets big on oral PCSK9 inhibitor with phase 3 program
Aug 25, 2023 8:35am
Cholesterol-focused Esperion loses appetite for Serometrix pact
Aug 1, 2023 10:46am
